Introduction {#Sec1}
============

Chronic obstructive pulmonary disease (COPD) is a disorder characterized by the progressive development of airway obstruction, which manifests as an accelerated decline in lung function, with symptoms such as breathlessness on physical exertion, deteriorating health status and exacerbations \[[@CR1]\].

Currently COPD is the fourth leading cause of death globally \[[@CR2]\], a major cause of morbidity and mortality, projected to become the world's third leading cause of mortality by 2020 \[[@CR3]\]. Characterized by progressive airflow limitation, COPD also has a major economic impact \[[@CR4]\].

According to the COPD Guidelines from 2011, which were updated in 2015, it is recommended to combine two long-acting bronchodilators in moderate-to-severe COPD patient groups \[[@CR5]\]. The combination of two bronchodilators with different mechanisms of action, such as long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs), are a successful treatment option for patients with COPD. Compared to single bronchodilators, the combination of LAMAs and LABAs demonstrates significant improvements in lung function without increasing the risk for adverse events \[[@CR5]--[@CR8]\]. The use of fixed-dose combinations (FDCs) of LABAs and LAMAs provide the opportunity to improve the accessibility and conformity compared to separate inhalers. Also, the dose of each substance used in the combination can be enhanced. An objection related to the development of an FDC is the arrangement of improved bronchodilation over monotherapy segments, while adjusting the associated adverse effects with efficacy \[[@CR9]\]. The safety and efficacy profiles of both LAMAs and LABAs are well accepted. However, it is important to recognize both the similarities and differences in both efficacy and safety, when combining two substances.

A new LABA/LAMA FDC, aclidinium/formoterol 400/12 μg twice-daily (BD), has recently been introduced in the management of COPD. The FDC, aclidinium/formoterol, is compared to placebo and aclidinium and formoterol as monotherapies in two pivotal, randomized, placebo-controlled studies \[ACLIFORM (ClinicalTrials.gov identifier NCT01462942) and AUGMENT (Clinicaltrials.gov identifier NCT01437397)\] \[[@CR10], [@CR11]\]. Results from both studies show a significant improvement in 24 h symptom control compared with placebo and aclidinium and formoterol monotherapies. Furthermore, in the aclidinium/formoterol group, the frequency of exacerbations is also reduced compared to placebo \[[@CR6]\].

Tiotropium 18 µg is a once-daily treatment and has been the first and most widely prescribed LAMA for COPD, considered as the standard of care in many countries \[[@CR12]\]. Based on the outcomes of the AUGMENT and ACLIFORM studies, it is expected that an FDC of aclidinium/formoterol will be more efficient on key COPD outcomes, compared to LAMA monotherapies. As there are no published direct head-to-head comparisons on the clinical efficacy and safety between FDC aclidinium/formoterol and tiotropium, alternative methodologies need to be employed to inform health-care practitioners.

For this reason, a systematic literature review and Bayesian indirect treatment comparison (ITC) were undertaken to assess the relative efficacy and safety of aclidinium/formoterol 400/12 μg BD versus tiotropium 18 μg once daily (OD) for the treatment of adult patients with moderate-to-severe COPD.

Methods {#Sec2}
=======

Data Sources {#Sec3}
------------

A systematic literature review was performed to identify randomized placebo-controlled trials (RCTs) reporting the safety and efficacy of aclidinium/formoterol 400/12 μg and tiotropium 18 μg compared to each other or placebo. Using a predefined strategy, MEDLINE^®^, MEDLINE in-process and EMBASE^®^ databases were searched simultaneously through the OVID platform, while the Cochrane Central Register of Controlled Trials was searched separately. The American Thoracic Society International Conference (2013) and European Respiratory Society International Congress (2013) were hand-searched for relevant abstracts. In addition, the search was also performed in ClinicalTrials.gov website. The searches were performed on March 24, 2014, for studies in English language with a time restriction from the year 1989 to March 2014. The predefined search strategies used were tailored for each database and are presented in Supplementary Table [1](#Tab1){ref-type="table"}. This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.Table 1Key characteristics of included studiesAuthor, Year and study acronymCompared treatmentRandomizedTrial designCenters/countriesInclusion criteriaBackground treatmentTrial durationRun-in periodChan 2007 \[[@CR19]\]\
BI trial: 205.259 \[[@CR20]\]Tiotropium 18 µg OD608RCT, PC, DB, MC, PG101 centers/Canada≥40 years old; ≥10 pack-years; FEV1 ≤65%; FEV1/FVC ≤70%; included if ≥1 exacerbation in the previous year, but not in the prior 6 weeks (later amended to incl 1 exacerbation in the past 2 years)Allowed: s dose oral corticosteroids, ICS, theophylline preparations, mucolytic preparations (not containing bronchodilators), LABAs48 weeksN/APlacebo305Tonnel 2008\
(TIPHON) \[[@CR21]\]Tiotropium 18 µg OD266RCT, PC, DB, MC123 centers/France≥40 years old; \>10 pack-years; FEV1 20--70%; FEV1/SVC ≤70%Allowed: stable doses of theophylline preparations (excluding 24 h preparations), mucolytics, ICS and oral steroids36 weeksN/APlacebo288Tashkin et al. 2008 (UPLIFT) \[[@CR12]\]\
Celli et al. 2009 \[[@CR22]\]Tiotropium 18 µg OD2987RCT, PC, DB, MC, PG490 centers/37 countries≥40 years old; \>10 pack-years; FEV1 ≤70%; FEV1/FVC ≤70%; excluded if exacerbation in prior 4 weeksAllowed: all respiratory medications, except other inhaled anticholinergic drugs4 yearsN/APlacebo3006Vogelmeier 2008 \[[@CR23]\]Formoterol 10 µg BID + Tiotropium 18 µg OD207RCT, PC, DB (TIO was OL), MC86 centers in Germany, Italy, Netherlands, Russian Federation, Poland, Czech Republic, Spain and HungaryFEV1 \<70%, FEV1/FVC \<70%; stable COPD; aged 40 years at COPD onset; smoking history of 10 pack-yearsAllowed: salbutamol, ICS monotherapy24 weeksN/AFormoterol 10 µg BID210Tiotropium 18 µg OD221Placebo209Niewoehner et al. 2005 \[[@CR24]\]Tiotropium 18 µg OD914RCT, PC, DB, MC, PG26 centers/USA≥40 years old; ≥10 pack-years; FEV1 ≤60%; FEV1/FVC ≤70%; excluded if not recovered from exacerbation ≥30 days priorAllowed: all other respiratory medications (including ICS and LABAs)\
Not allowed: open-label anticholinergic bronchodilator6 monthsN/APlacebo915Brusasco 2003 \[[@CR25]\]Tiotropium 18 µg OD402RCT, PC, DB, MC, DD, PG\# Centers NR/18 countries\>40 years old; \>10 pack-years; FEV1 ≤65%; FEV1/FVC ≤70%;NR24 weeksN/ASalmeterol 50 µg BID405Placebo400Donohue et al. 2002 \[[@CR26]\]\
Donohue et al. 2003 \[[@CR27]\]Tiotropium 18 µg OD209RCT, PC, DB, MC, DD, PG39 countries/12 countries≥40 years old; \>10 pack-years; FEV1 ≤60%;FEV1/FVC ≤70%;Allowed: usual ICS and oral steroids;\
Not allowed: inhaled anticholinergic LABAs24 weeksN/ASalmeterol 50 µg BID213Placebo201Casaburi 2002 \[[@CR28]\]Tiotropium 18 µg OD550Two RCTs, PC, DB, MC50 centers, countries NR≥40 years old; ≥10 pack-years; FEV1 ≤65%;FEV1/FVC ≤70%;Allowed: stable doses of theophylline, ICS, oral prednisone56 weeksN/APlacebo371Donohue 2010 \[[@CR29]\]Indacaterol 150 µg OD420RCT, PC, DB (except for tiotropium arm), MC, DD; adaptive seamless\# Centers NR/USA, Sweden, Turkey, Germany≥40 years old; ≥20 pack-years; FEV1 peak \<80% (predicted); 30% ≥FEV1/FVC \<70%;Allowed: continue ICS monotherapy if stable for 1 month before screening; albuterol (as needed)\
Excluded: anticholinergic bronchodilators or β2-agonists were fixed-combination β2-agonist/ICS were switched to ICS monotherapy at an equivalent dose26 weeksN/AIndacaterol 300 µg OD418Tiotropium 18 µg OD420Placebo425Bateman et al. 2013 \[[@CR8]\]\
Frith et al. 2013 \[[@CR30]\]\
SHINE CSR data (by Novartis) \[[@CR36]\]QVA 149 110/50 µg OD475RCT, MC, DB, PG, PC, active controlled trial301 sites in 27 countries: Argentina; Australia; Bulgaria; Canada; China; Finland; France; Germany; Guatemala; Hungary; India; Japan; Mexico; Netherlands; Panama; Philippines; Poland; Romania; Russia; Slovakia; South Africa; Spain; Switzerland; Taiwan; Turkey; UK; USA≥40 years, moderate-to-severe stable COPD, smoking history of ≥10 pack-years, peak FEV1 ≥30% and \<80% of predicted normal and post-bronchodilator FEV1/FVC \<0.70Excluded: oxygen (\>15 h per day); antibiotics, systemic steroids (oral or OV). During washout, patients discontinued LABAs and LABA/ICS combinations.\
Allowed: selective serotonin reuptake inhibitors; inactivated vaccine; ICS; intranasal CS; H1 antagonists26 weeks2 weeksIndacaterol 150 µg OD477Glycopyrronium 50 µg OD475Tiotropium 18 µg OD483Placebo234Ambrosino et al. 2008 \[[@CR31]\]Tiotropium 18 µg OD117RCT, MC, DB, PC, PG12 sites in Italy≥40 years old; \>10 pack-years; FEV1 predicted ≤60%;FEV1/FVC ≤70%Excluded: anti-arrhythmic drugs; other β2-agonists (long and short acting) and inhaled anticholinergic medications (other than study drugs)25 weeks4 weeksPlacebo117Kerwin et al. 2012 \[[@CR32]\]\
(GLOW2 study)NVA237 50 µg OD529RCT, DB, MC, PC, PG,\
Tiotropium was OLNR≥40 years old; ≥10 pack-years; FEV1 peak ≥30% and \<80% of the predicted normal; FEV1/FVC \<70%; moderate-to-severe stable COPDAllowed: inhaled or intranasal CS and H1-antagonists; salbutamol/albuterol as rescue medication\
Not allowed: LAMAs (min 7 days before run-in); LABAs or LABA/ICS combinations (minimum 48 h before run-in)52 weeks2 weeksTiotropium 18 µg OD268Placebo269Cooper et al 2012 \[[@CR33]\]Tiotropium 18 µg OD260RCT, DB, MC, PG, PCNR≥40 years old; ≥10 pack-years; moderate-to-severe stable COPD; FEV1 peak ≤65% predicted; trough FEV1 ≤60%; FEV1/FVC \<70%; Medical Research Council dyspnea score ≥2 (based on a 1--5 scale)Excluded: inhaled anticholinergics during a screening visit\
Allowed: all respiratory medications other than inhaled anticholinergics during a screening visit (Visit 1) in which an incremental treadmill protocol was conducted96 weeks2 weeksPlacebo259CSR: M/40464/30R \[[@CR34]\]Aclidinium/Formoterol 400/12 µg BID385RCT, PG, DB, PC, MC, multinational, phase III193 centers in 22 countries: Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, the Netherlands, Poland, Romania, Russia, Slovakia, South Africa, South Korea, Spain, Sweden, Ukraine, UK≥40 years; smoking history of ≥10 pack-years; FEV1/FVC \<70%; with a diagnosis of moderate-to-severe COPD. Peak FEV~1~ 30% ≤FEV~1~ \<80% of the predicted normal valueExcluded concomitant drugs: anticholinergic drugs; β2-agonists; terbutaline or metaproterenol; formoterol, salmeterol, indacaterol; combination of SABA and an anticholinergic agent (e.g., Combivent); inhaled fixed-dose combinations of LABAs and corticosteroids (e.g., Symbicort, Advair); corticosteroid drugs; cromolyn sodium, nedocromil; leukotriene modifiers; methyl-xanthines; phosphodiesterase 4 inhibitors; β1-blocking agents\
Allowed concomitant drugs: oral sustained release methyl-xanthines, oxygen therapy on an as-needed basis, oral or parenteral corticosteroids, ICS, switching patients from combinations of LABAs and corticosteroids to ICS as monotherapy24 weeks2--3 weeksAclidinium/Formoterol 400/6 µg BID381Aclidinium 400 µg BID385Formoterol 12 µg BID384Placebo194CSR: LAC-MD-31 \[[@CR35]\]Aclidinium/Formoterol 400/12 µg BID338RCT, DB, PC, PG, MC, active controlled, multinationalA total of 222 study centers located in the USA (193 centers), Canada (10 centers), Australia (11 centers), and New Zealand (8 centers) screened patients for the study. A total of 205 of these study centers randomized patients (178 in the USA, 9 in Canada, 10 in Australia, and 8 in New Zealand)≥40 years, moderate-to-severe stable COPD, smoking history of ≥10 pack-years, peak FEV1 ≥30% and \<80% of predicted normal and post bronchodilator FEV1/FVC \<0.70Allowed: ICS, systemic corticosteroids (oral or parenteral corticosteroids), oxygen, SABAs and methylxanthines24 weeks2--3 weeksAclidinium/Formoterol 400/6 µg BID338Aclidinium 400 µg BID340Formoterol 12 µg BID339Placebo337*BID* twice daily, *COPD* chronic obstructive pulmonary disease, *CS* corticosteroid, *CSR* clinical study reports, *DB* double blind, *DD* double dummy, *FEV1* forced expiratory volume in 1 s, *FVC* forced vital capacity, *ICS* inhaled corticosteroids, *LABA* long-acting β2-agonists, *MC* multicenter, *NR* not reported, *OD* once daily, *OL* open label, *PC* placebo controlled, *PG* parallel group, *RCT* randomized controlled trial, *SABA* short-acting beta agonists, *SD* standard deviation, *TIO* tiotropium, *USA* United States of America. Arms in gray are not of interest for this study

Study Selection Process {#Sec4}
-----------------------

The relevance of each citation identified was assessed according to predefined abstract selection criteria (Supplementary Table S2). First, titles and abstracts were screened for eligibility, and then full texts of the selected articles were assessed by one researcher and checked against the original study by another. Those that met the inclusion criteria were included for data extraction.

The studies of interest were RCTs with duration of 22--26 weeks, including adults with moderate-to-severe COPD, reporting on aclidinium/formoterol 400/12 μg BD (using the Genuair^®^ device \[AstraZeneca AB, Södertälje, Sweden\]) or tiotropium 18 μg OD (using the Handihaler^®^ device \[Boehringer Ingelheim, Ridgefield, USA\]) compared with each other or placebo. The efficacy outcomes of interest were: trough forced expiratory volume in 1 s (FEV~1~) (pre-bronchodilatory), peak FEV~1~ (post-bronchodilatory), St. George's Respiratory Questionnaire (SGRQ) score, Transition Dyspnea Index (TDI) focal score and the % of patients with ≥1 exacerbations. The safety outcomes of interest were: adverse events, serious adverse events, hospitalization and mortality. In all cases, outcomes reported in the range of 22--26 weeks were grouped as 24 weeks.

Data Abstraction and Quality Assessment {#Sec5}
---------------------------------------

For the studies identified that met the inclusion criteria, details were extracted on population characteristics, interventions, outcomes and the study design of interest at 24 weeks (22--26 weeks) (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, Supplementary Table S5, Supplementary Table S6). Data abstraction was performed by one researcher and verified against the original study publication by another. Data of interest presented in graphs were extracted using DigitizeIT version 4.1 software (DigitizeIT, Braunschweig, Germany).Table 2Key patient characteristics at baseline for included studies (only arms of interest)Author, year and study acronymTreatmentRandomizedMale (%)Age (SD) (years)Current smokerICS useDuration COPD (SD) (years)Pack-years (SD)FEV~1~ mean (SD) (liters)FEV~1~% pred. (SD)% FEV~1~/FVC (SD)FVC mean (SD) (liters)Chan 2007 \[[@CR19]\]\
BI trial: 205.259 \[[@CR20]\]Tiotropium 18 µg OD6085967.0 (8.7)32%66%9.9 (8.1)50.2 (22.6)0.97 (0.39)39.4 (13.0)46.4 (12.0)2.11 (0.76)Placebo3056167.0 (9.1)30%71%9.9 (7.9)51.0 (26.3)0.96 (0.38)39.3 (14.0)46.3 (12.0)2.11 (0.73)Tonnel 2008\
(TIPHON) \[[@CR21]\]Tiotropium 18 µg OD2668765.0 (9.7)24%38%7.9 (7.6)44.4 (21.3)1.38 (0.44)47.5 (13.3)55.3 (11.3)2.50 (0.68)Placebo2888564.0 (10.1)30%36%8.0 (7.9)43.0 (22.5)1.35 (0.46)46.2 (12.4)54.6 (11.3)2.49 (0.75)Tashkin et al. 2008 (UPLIFT) \[[@CR12]\]\
Celli et al. 2009 \[[@CR22]\]Tiotropium 18 µg OD29877565.0 (8.4)29%62%9.9 (7.6)49.0 (28.0)1.10 (0.40)39.5 (12.0)42.4 (11.0)2.63 (0.81)Placebo30067465.0 (8.5)30%62%9.7 (7.4)48.4 (27.9)1.09 (0.40)39.3 (12.0)42.1 (11.0)2.63 (0.83)Vogelmeier 2008 \[[@CR23]\]Tiotropium 18 µg OD2217963.4 (9.5)NRNR6.9 (6.3)38.6 (19.3)1.50 (0.39)51.6 (11.2)54.4 (9.6)50.1NR (NR)Placebo2097862.5 (8.6)NRNR6.7 (6.1)40.1 (22.8)1.50 (0.39)51.1 (11.0)53.5 (10.0)NR (NR)Niewoehner et al. 2005 \[[@CR24]\]Tiotropium 18 µg OD9149867.6 (8.7)29%61%12.2 (10.4)67.4 (35.4)1.04 (0.40)35.6 (12.6)47.9 (11.5)NR (NR)Placebo9159968.1 (8.5)30%58%11.9 (10.5)69.4 (36.6)1.04 (0.40)35.6 (12.6)47.7 (11.1)NR (NR)Brusasco 2003 \[[@CR25]\]Tiotropium 18 µg OD4027763.8 (8.0)NRNR9.0 (7.3)44.1 (22.9)1.12 (0.39)39.2 (11.6)43.7 (9.7)2.59 (0.75)Placebo4007664.6 (8.6)NRNR9.8 (7.4)42.4 (22.7)1.09 (0.40)38.7 (12.1)42.3 (9.2)2.60 (0.78)Donohue et al. 2002 \[[@CR26]\]\
Donohue et al. 2003 \[[@CR27]\]Tiotropium 18 µg OD2097464.5 (7.9)NR66%9.2 (7.8)47.0 (25.0)1.11 (0.39)41.0 (NR)43.6 (9.8)2.54 (0.71)Placebo2017565.6 (7.8)NR66%9.7 (7.9)46.0 (24.0)1.06 (0.36)41.0 (NR)41.3 (8.7)2.58 (0.74)Casaburi 2002 \[[@CR28]\]Tiotropium 18 µg OD5506765.0 (9.0)NR44%8.6 (7.4)63.0 (31.0)1.04 (0.41)39.1 (13.7)45.8 (11.6)2.31 (0.79)Placebo3716365.0 (9.0)NR40%8.1 (6.8)59.0 (30.0)1.00 (0.44)38.1 (14.1)45.5 (11.6)2.23 (0.78)Donohue 2010 \[[@CR29]\] Tiotropium 18 µg OD4206564.0 (8.8)NR35%NR50.0 (25.1)1.45 (0.51)53.9 (15.6)52.7 (10.0)NR (NR)Placebo4256163.6 (8.9)NR40%NR49.7 (24.0)1.51 (0.49)56.1 (14.3)53.4 (10.0)NR (NR)Bateman et al. 2013 \[[@CR8]\]\
Frith et al. 2013 \[[@CR30]\]\
SHINE CSR data (by Novartis) \[[@CR36]\]Tiotropium 18 µg OD4807563.5 (8.7)39%59%6.1 (5.5)NR1.30 (0.50)55.1 (13.5)49.2 (10.8)NR (NR)Placebo2327364.4 (8.6)40%58%6.4 (5.7)NR1.30 (0.50)55.2 (12.7)48.6 (10.4)NR (NR)Ambrosino et al. 2008 \[[@CR31]\]Tiotropium 18 µg OD1178367.8 (7.8)NR42%10.9 (9.8)38.3 (25.2)1.10 (0.40)42.5 (13.3)47.3 (11.8)2.40 (0.70)Placebo1178566.9 (7.3)NR52%11.3 (9.5)35.0 (22.4)1.10 (0.40)40.3 (12.6)45.2 (10.4)2.50 (0.80)Kerwin et al. 2012 \[[@CR32]\]\
(GLOW2 study)Tiotropium 18 µg OD2676363.9 (8.2)44%52%7.5 (6.6)50.2 (28.0)Trough: 1.30 (0.50)\*\
Peak: 1.50 (0.50)\*\*56.0 (13.0)50.3 (10.5)NR (NR)Placebo2686563.6 (9.1)46%51%7.4 (6.6)48.0 (24.0)Trough: 1.40 (0.50)\*\
Peak: 1.50 (0.50)\*\*56.4 (14.0)50.9 (10.5)NR (NR)Cooper et al. 2012 \[[@CR33]\]Tiotropium 18 µg OD2607764.7 (8.2)35%61%NR52.2 (29.0)1.25 (0.41)44.5 (11.7)46.7 (11.8)2.75 (0.84)Placebo2597864.5 (8.5)33%59%NR51.0 (26.3)1.25 (0.42)44.2 (12.1)46.7 (11.1)2.72 (0.80)CSR: M/40464/30R \[[@CR34]\]Aclidinium/Formoterol 400/12 µg BID3856862.7 (8.1)47%22%8.5 (6.3)40.8 (21.5)1.42 (0.49)50.1 (14.3)48.1 (10.4)3.00 (0.87)Placebo1947164.2 (8.0)49%20%8.6 (6.2)41.9 (21.0)1.42 (0.54)50.1 (13.7)47.8 (10.4)3.03 (0.94)CSR: LAC-MD-31 \[[@CR35]\]Aclidinium/Formoterol 400/12 µg BID3355064.2 (8.9)52%9%8.8 (6.4)53.3 (27.2)Trough: 1.33 (0.53)\*\
Peak: 1.53 (0.54)\*\*Trough: 46.4 (13.9)\*\
Peak: 53.2 (13.4)\*\*50.6 (10.9)Trough: 2.69 (0.85)\*\
Peak: 3.04 (0.89)\*\*Placebo3325363.5 (8.9)51%7%8.4 (6.3)53.3 (28.5)Trough: 1.34 (0.54)\*\
Peak: 1.55 (0.55)\*\*Trough: 45.5 (14.1)\*\
Peak: 52.6 (13.3)\*\*50.2 (11.1)Trough: 2.75 (0.91)\*\
Peak: 3.13 (0.95)\*\**BID* twice daily, *COPD* chronic obstructive pulmonary disease, *CSR* clinical study report, *FEV* ~*1*~ forced expiratory volume in 1 s, *FVC* forced vital capacity, *ICS* Inhaled corticosteroids, *NR* not reported, *OD* once daily, *SD* standard deviation\* Trough FEV~1~ (Pre-bronchodilatory)\*\* Peak FEV~1~ (post-bronchodilatory)

For continuous outcomes, the change from baseline (CFB) and the associated sampling variance were extracted or calculated based on the available data. For dichotomous outcomes, the number of patients experiencing an event was extracted or estimated based on the reported percentages and intention to treat population, and the total patient-years of follow-up were calculated.

The validity of each trial used in the ITC was assessed using the National Institute of Health and Clinical Excellence (NICE) checklist. The results of this assessment were not explicitly used in the ITC, but serve as additional information to determine the quality of the evidence base when interpreting the results (Supplementary Table S3).

Data Synthesis: Indirect Treatment Comparison {#Sec6}
---------------------------------------------

The existence of a connection between the treatments of interest via a common control (placebo), as well as the study design and patient characteristics of the identified studies, was used to assess the feasibility of a valid ITC \[[@CR13]\]. Subsequently, the identified evidence was used to perform an ITC within a Bayesian framework to simultaneously synthesize the results of the included studies and obtain relative treatment effects \[[@CR14], [@CR15]\]. A linear model with normal likelihood distribution was used for continuous outcomes, and a Poisson likelihood with a log link for the dichotomous outcomes \[[@CR16]\]. Flat (non-informative) prior distributions, normal with zero mean and variance of 10,000, were assumed for the relative treatment effects of all outcomes. A uniform distribution with range 0--5 was used as the prior of the between-study standard deviation.

For each outcome, a fixed and a random effects model was evaluated. The goodness of fit of each model to the data was assessed using the deviance information criterion \[[@CR17]\]. The posterior densities were estimated using the Markov chain Monte Carlo (MCMC) simulations based on 80,000 iterations on three chains, with a burn-in of 20,000 iterations. Convergence assessment was based on visual inspection of trace plots and accuracy of the posterior estimates using the Monte Carlo error for each parameter. WinBUGS 1.4.3 (MRC Biostatistics Unit, Cambridge, UK) statistical software was used for the analyses and the models were based on those defined by Dias et al. \[[@CR18]\]. The posterior distributions were summarized with the median to reflect the most likely value of the estimate, and the 2.5th and 97.5th percentile to capture the 95% credible interval (CrI). For each end point, the probability that each treatment was better than a certain comparator was established.

Results {#Sec7}
=======

Search and Selection Results {#Sec8}
----------------------------

After searching, a total of 2401 abstracts from the databases and 88 clinical trials from ClinicalTrials.gov were identified (Fig. [1](#Fig1){ref-type="fig"}). Following the abstracts and full-text publication screening stages, 17 full-text publications \[[@CR8], [@CR12], [@CR19]--[@CR33]\] were identified and 3 clinical study reports \[[@CR34]--[@CR36]\] were provided by AstraZeneca. In total, the evidence base comprised 15 different studies; 13 studies \[[@CR8], [@CR12], [@CR19]--[@CR33], [@CR36]\] compared tiotropium 18 μg to placebo (14,697 patients) and two studies \[[@CR34], [@CR35]\] compared aclidinium/formoterol 400/12 μg to placebo (1246 patients).Fig. 1Flowchart of the study selection process. *ATS* American Thoracic Society, *CSR* clinical study report, *ERS* European Respiratory Society

Study Characteristics {#Sec9}
---------------------

An overview of the study characteristics is presented in Table [1](#Tab1){ref-type="table"}. All studies were multicenter, placebo-controlled RCTs. Twelve studies \[[@CR8], [@CR12], [@CR19]--[@CR22], [@CR24]--[@CR28], [@CR30], [@CR31], [@CR33], [@CR36]\] were double-blind and three \[[@CR23], [@CR29], [@CR32]\] included tiotropium as an open-label arm. The included studies varied in terms of the number of patients randomized to each treatment, ranging from 117 \[[@CR31]\] to 3006 \[[@CR12], [@CR22]\]. The trial duration varied from 96 weeks \[[@CR33]\] to 24 weeks \[[@CR23]--[@CR27], [@CR34], [@CR35]\]. The use of ICS (inhaled corticosteroids) as a background treatment was allowed in all studies and patients were permitted a short-acting beta-agonist as rescue medication (salbutamol or albuterol). The studies were of comparable quality, according to the results of the assessment using NICE questionnaire (Supplementary Table S3). In general, the method of randomization and concealment of treatment allocation was well reported.

Patient Characteristics {#Sec10}
-----------------------

An overview of the main patient characteristics is provided in Table [2](#Tab2){ref-type="table"}. The enrolled patients were adults with a COPD diagnosis. The studies included a predominantly male population, ranging from 50% \[[@CR35]\] to 99% \[[@CR24]\], while in three studies \[[@CR21], [@CR24], [@CR31]\] more than 80% of the included patients were male in both arms. The patients' average age across all the studies was similar (range 63--68 years). Overall, spirometry measures were fairly consistent at baseline. According to the inclusion criteria, most studies required an FEV~1~/forced vital capacity (FVC) of less than or equal to 0.70 and an FEV~1~% predicted range between 30% and 80%. The mean FEV~1~% predicted at baseline ranged between 35.6% and 56.4%. FEV~1~ at baseline ranged from 0.96 liter (L) to 1.55 L. The FEV~1~/FVC at baseline was reported to be between 41.3% and 55.3%. Across all the included studies, the percentage of patients per arm that used ICS at baseline ranged between 7% and 71%. The percentage was lower in both aclidinium/formoterol trials (7% to 9% for LAC-MD-31 and 19--22% for M/40464/30R) than in the other studies (35--71%). Furthermore, all studies included patients who were current or ex-smokers. In studies where the percentage of current smokers was reported, it ranged from 40% to 53%. Six studies (reported in 7 publications: \[[@CR23], [@CR25]--[@CR29], [@CR31]\]) did not report the percentage of current smokers. The mean number of pack-years ranged from 35.0 to 69.4 years.

Indirect Treatment Comparison {#Sec11}
-----------------------------

Despite some differences identified across the studies in terms of study design and patient characteristics, the 15 RCTs (reported in 20 publications) are considered to be broadly comparable and the ITC was feasible \[[@CR13]\]. The diagram of the trials included in the ITC is shown in Fig. [2](#Fig2){ref-type="fig"}.Fig. 2Network of studies included in the indirect treatment comparison

Efficacy Outcomes {#Sec12}
-----------------

Individual study results for efficacy outcomes are presented in Supplementary Table S5, where data not reported but estimated are denoted by an asterisk. The results of the ITC analysis are presented in Table [3](#Tab3){ref-type="table"}. Regarding lung function, for both outcomes considered in this study, i.e., peak and trough FEV~1~, aclidinium/formoterol 400/12 µg appeared to be more efficacious compared to tiotropium 18 µg at 24 weeks.Table 3ITC results for aclidinium/formoterol versus tiotropium at 24 weeksOutcomeMean95% CrIProb. better (%)Efficacy Peak FEV~1~ (DCFB, mL)143.2(112.00, 174.50)\>99 Trough FEV~1~ (DCFB, mL)26.21(−2.31, 54.72)96 SGRQ total score (DCFB, units)−0.52(−2.21, 1.17)73 SGRQ responders (OR, ≥4 units improvement)1.16(0.47, 2.87)68 TDI focal score (difference vs. comparator)0.54(0.09, 0.99)\>99 TDI responders (OR, ≥1 points improvement)1.51(1.11, 2.06)\>99 Patients with at least 1 exacerbation (OR)1.03(0.73, 1.47)43Safety Adverse events (OR)1.16(0.86, 1.55)17 Serious adverse events (OR)1.22(0.71, 2.16)24 Hospitalization1.03(0.37, 2.90)48*CrI* credible interval, *DCFB* difference in change from baseline, *FEV* ~*1*~ forced expiratory volume in 1 s, *mL* milliliters, *OR* odds ratio, *Prob. better* probability of aclidinium/formoterol being a better treatment than tiotropium for this outcome, *SGRQ* St. George's Research Questionnaire, *TDI* Transitional Dyspnea Index

Regarding health-related quality of life, as measured by SGRQ total score, the individual study results for aclidinium/formoterol demonstrate high variation between the M/40464/30R and LAC-MD-31 studies. The cause of this variation is unknown and cannot be explained by differences in study design or patient characteristics. The heterogeneity is reflected in the results of the ITC by means of wide credible intervals with a difference in CFB of −0.52 (95% CrI −2.21, 1.17). Similarly, for the % of responders (patients with \>4 units reduction), the relative effect is heterogeneous with variation between M/40464/30R and LAC-MD-31 studies with an odds ratio (OR) 1.16 \[95% CrI (0.47, 2.87)\]. Due to this high variation, the results should be interpreted with caution; aclidinium/formoterol appeared to be comparable to tiotropium for both SGRQ total score and % responders.

Aclidinium/formoterol was more efficacious than tiotropium in improving breathlessness measured by TDI and % responders (i.e., patients with \>1 point increase from baseline).

With regard to the percentage of patients with at least one exacerbation, aclidinium/formoterol was likely to be better compared to placebo with OR of 0.78 \[95% CrI (0.56, 1.08)\] and comparable to tiotropium with OR 1.03 (95% CrI \[0.73, 1.47\]). For this outcome, the time period of 24 weeks is relatively short, as the results are heavily dependent on the recent history of the patients recruited (e.g., if they had an exacerbation within the last months before recruitment, see inclusion/exclusion criteria in Table [1](#Tab1){ref-type="table"}). Furthermore, the percentage of patients with at least one exacerbation in the placebo arm is almost 3.5 times higher in Donohue et al. 2002 and 2003 \[[@CR26], [@CR27]\] (45.8%) than in M/40464/30R (13.4%) \[[@CR34]\], suggesting differences in COPD severity, in exacerbation-related study inclusion criteria or in the way the exacerbations were defined/reported. For these reasons, the results of the ITC shall be interpreted with caution.

Safety Outcomes {#Sec13}
---------------

For the safety outcomes, the individual study results are presented as: number of patients with an event (n); number of patients included in the analysis (N); and proportion of patients with an event per treatment arm (Supplementary Table S6).

Compared to placebo, aclidinium/formoterol \[OR 1.19; 95% CrI (0.95, 1.49)\], and tiotropium \[OR 1.03; 95% CrI (0.85, 1.24)\] resulted in a mean OR above 1, suggesting an advantage for placebo, although not a significant one as the CrI included 1 in all cases. In both cases, the results of this analysis should be interpreted with extreme caution, first due to the limited number of studies, the time of assessment (24 weeks is a rather short period for safety outcomes) and potential differences in the way this outcome is reported in each study.

In the results of the ITC for serious adverse events for active treatments compared to placebo, the median OR for all active treatments was above 1 suggesting an advantage for placebo, but in all cases the credible intervals included 1; thus, the difference cannot be considered as significant. In line with this in pairwise comparisons between the active treatments, the CrI include 1 in all cases. Regarding AEs, the results of this analysis should be interpreted with extreme caution, due to the limited number of studies and the time of assessment (24 weeks is a rather short period for safety outcomes).

The results of the ITC regarding the proportion of patients with hospitalization within 24 weeks are uncertain for aclidinium/formoterol versus placebo with an OR 0.65 \[95% CrI (0.22, 1.64)\], mainly due to the lack of data, while for tiotropium the OR was 0.59 \[95% CrI (0.46, 0.74)\] versus placebo. Similarly, aclidinium/formoterol was comparable to tiotropium with OR 1.03 \[95% Crl (0.37, 2.90)\], but with high uncertainty.

The ITC for mortality was not (computationally) feasible, as the majority of the studies reported zero events (deaths) which lead the algorithm (MCMC) to numerical overflow, even when applying a continuity correction of 0.5. With such a large proportion of trials with zero events, estimation of a treatment effect and its variance becomes practically impossible. The individual study results for mortality are presented in Supplementary Table S6.

Discussion {#Sec14}
==========

Based on the results of the ITC, aclidinium/formoterol is expected to be more efficacious than tiotropium in terms of peak FEV~1~, TDI focal score and TDI responders. Regarding trough FEV1, aclidinium/formoterol is expected to be favorable compared to tiotropium. In all other efficacy and safety end points, aclidinium/formoterol and tiotropium are expected to result in similar (comparable) outcomes. The analysis for mortality was not feasible because the majority of the studies reported zero events.

A few other studies compared LABA/LAMA combinations versus tiotropium in a head-to-head trial. Both the SHINE study (ClinicalTrials.gov identifier, NCT01202188) \[[@CR8]\] and SPARK study (ClinicalTrials.gov identifier, NCT01120691) \[[@CR37]\] compared QVA149 (indacaterol 110 mg/glycopyrronium 50 mg) to tiotropium. The SHINE study reports comparable results to our study with superior improvements in lung function for the QVA149 group compared to tiotropium. The safety results are comparable to placebo and with no additional safety signal compared to tiotropium \[[@CR8]\]. The SPARK study also shows similar results, with a significant reduction in the rate of all exacerbations, and a significant improvement in trough FEV1 and health status favoring the dual LABA/LAMA bronchodilator QVA149 versus tiotropium. Furthermore, no safety differences between the dual LABA/LAMA bronchodilator and tiotropium are found \[[@CR37]\]. Decramer et al. \[[@CR38]\] and Maleki-Yazdi et al. \[[@CR39]\] both compared umeclidinium plus vilanterol versus tiotropium. Both studies report a significant improvement in lung function compared to tiotropium, and no safety differences are found between the groups.

It is challenging to demonstrate the relevance of the end points on COPD studies comparing combination therapy to monotherapy. To determine the clinical effectiveness, the minimum clinically important difference (MCID) is often used to acknowledge a clinically significant effect. This measure is however focused on the comparison of a monotherapy versus placebo. When comparing a combination therapy to a monotherapy, uncertainty has occurred if the MCID is a valid measure, because the differences in effects tend to be smaller since both arms receive active therapy. Jones et al. \[[@CR40]\] discuss this issue and have introduced the 'minimum worthwhile incremental advantage' which can be used to describe the percentage of patients experiencing improvement at or above MCID when adding active treatment on top of another active treatment or when comparing two active treatments to each other \[[@CR6], [@CR40]\].

Furthermore, there are a number of other potential limitations to this analysis. First, as for any meta-analysis, inherent limitations are related to the potential for within-study bias and publication bias. Furthermore, there are differences in the definitions of exacerbations and in study methodology, populations that could introduce bias. For example, across all the included studies, the percentage of patients per arm that used ICS at baseline ranged between 7% and 71%. The percentage was lower in both aclidinium/formoterol trials (7--9% for LAC-MD-31 and 19--22% for M/40464/30R) than in the other studies (35--71%). Also, for the SGRQ total score outcome, the CFB versus placebo reported for aclidinium/formoterol 400/12 demonstrated high variation between the M/40464/30R and LAC-MD-31 studies. The cause of this variation is unknown and cannot be explained by the study designs or patient characteristics.

In addition, bias could be introduced due to the imbalances in potential treatment effect modifiers (e.g., FEV~1~ predicted at baseline) and differences in the background medications. Due to the lack of access to individual patient data and the low number of studies (especially for aclidinium/formoterol), it was not feasible to further explore these differences.

Furthermore, it is considered complicated to include safety in indirect comparisons, since this is not a straightforward approach. However, we decided to include safety next to efficacy outcomes, since a benefit--risk assessment will add important data about the intervention.

Conclusion {#Sec15}
==========

The results of this analysis suggest that aclidinium/formoterol is more efficacious with a similar safety profile compared to tiotropium.
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